General Information |
| Description |
To evaluate the safety and efficacy of tacrolimus in patients with Parkinson's disease after transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum. |
| Clinical trials phase |
Phase 3 |
| Start date (estimated) |
2018-08-01 |
| End date (estimated) |
2023-12-31 |
| Clinical feature |
| Label |
Parkinson's disease |
| Link |
http://purl.obolibrary.org/obo/DOID_14330 |
| Description |
A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000033565 |
| Other study identifiers |
| Name |
UMIN000033565 |
| Description |
UMIN Clinical Trials Registry (UMIN-CTR) |
|
| Source weblink |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038279 |
| Sponsors |
Kyoto University Hospital
|
Cells |
| Which differentiated cell type is used |
| Label |
dopaminergic neuron |
| Link |
http://purl.obolibrary.org/obo/CL_0000700 |
| Description |
A neuron that releases dopamine as a neurotransmitter. |
|
Recruitment |
| Recruitment Status |
Suspended |
| Estimated number of participants |
7 |
